If you're a biotech investor, you've probably heard of both Recursion Pharmaceuticals (NASDAQ: RXRX) and CRISPR Therapeutics, (NASDAQ: CRSP) two of the most followed biotechs this year. Both companies ...
Dec 8 (Reuters) - Recursion Pharma, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths in the colon in ...
We recently compiled a list of the Blackrock’s 30 Most Important AI Stocks. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against the other ...
Recursion could have three different revenue streams one day. Right now, it only has one but another may soon be within reach. It'll need all three going full bore to turn its investors into ...
For years, drug developers that apply artificial intelligence (AI) have touted the benefits of the technology—the prospect of speedier development of new treatments at lower cost, thus reducing the ...
Recursion Pharmaceuticals RXRX is strategically leveraging its AI-powered drug discovery platform through multiple high-value collaborations, positioning itself for long-term growth and sustainability ...
The timing of upcoming catalysts is a key consideration when comparing biotechs. Recursion Pharmaceuticals may make more revenue soon, but not from its pipeline. CRISPR Therapeutics is approaching the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results